SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Proceedings of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis B. September 14–16, 2002. Geneva, Switzerland. J. Hepatol. 2003; 39 (Suppl 1): S1S235.
  • 2
    Moloughney BW. Transmission and postexposure management of bloodborne virus infections in the health care setting: Where are we now? CMAJ 2001; 165 : 44551.
  • 3
    Dienstag JL. Hepatitis B virus infection. N. Engl. J. Med. 2008; 359 : 1486500.
  • 4
    Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004; 11 : 97107.
  • 5
    Kane M. Global programme for control of hepatitis B infection. Vaccine 1995; 13 (Suppl 1): S47S49.
  • 6
    Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 2001; 94 : 1536.
  • 7
    Rosenheim Advisory Group. Hepatitis and the Treatment of Chronic Renal Failure. London: Department of Health and Social Security, 1972.
  • 8
    Centers for Disease Control. Hepatitis: Control Measures for Hepatitis B in Dialysis Centers. HEW publication no. (CDC) 78-8358. Altlanta, GA: US Department of Health, Education and Welfare, 1977.
  • 9
    Dinits-Pensy M, Forrest GN, Cross AS, Hise MK. The use of vaccines in adult patients with renal disease. Am. J. Kidney Dis. 2005; 46 : 9971011.
  • 10
    Stevens CE, Szmuness W, Goodman AI, Weseley SA, Fotino M. Hepatitis B vaccine: Immune responses in haemodialysis patients. Lancet 1980; 2 : 121113.
  • 11
    Desmyter J, Colaert J, De Groote G et al. Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Double-blind placebo-controlled trial. Lancet 1983; 2 : 13238.
  • 12
    Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin. Dial. 2005; 18 : 5261.
  • 13
    Burdick RA, Bragg-Gresham JL, Woods JD et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int. 2003; 63 : 22229.
  • 14
    Johnson DW, Dent H, Yao Q et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia–Pacific countries: Analysis of registry data. Nephrol. Dial. Transplant. 2009; 24 : 1598603.
  • 15
    Yakaryilmaz F, Gurbuz OA, Guliter S et al. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren. Fail. 2006; 28 : 72935.
  • 16
    Ferreira RC, Teles SA, Dias MA et al. Hepatitis B virus infection profile in hemodialysis patients in Central Brazil: Prevalence, risk factors, and genotypes. Mem. Inst. Oswaldo Cruz 2006; 101 : 68992.
  • 17
    Carrilho FJ, Moraes CR, Pinho JR et al. Hepatitis B virus infection in Haemodialysis Centres from Santa Catarina State, Southern Brazil. Predictive risk factors for infection and molecular epidemiology. BMC Public Health 2004; 4 : 13.
  • 18
    Ribot S, Rothstein M, Goldblat M, Grasso M. Duration of hepatitis B surface antigenemia (HBs Ag) in hemodialysis patients. Arch. Intern. Med. 1979; 139 : 17880.
  • 19
    Wong PN, Fung TT, Mak SK et al. Hepatitis B virus infection in dialysis patients. J. Gastroenterol. Hepatol. 2005; 20 : 164151.
  • 20
    Bond WW, Favero MS, Petersen NJ, Gravelle CR, Ebert JW, Maynard JE. Survival of hepatitis B virus after drying and storage for one week [letter]. Lancet 1981; 1 : 55051.
  • 21
    Karkar A, Abdelrahman M, Ghacha R, Malik TQ. Prevention of viral transmission in HD units: The value of isolation. Saudi J. Kidney Dis. Transpl. 2006; 17 : 1838.
  • 22
    Salo RJ, Salo AA, Fahlberg WJ, Ellzey JT. Hepatitis B surface antigen (HBSAg) in peritoneal fluid of HBSAg carriers undergoing peritoneal dialysis. J. Med. Virol. 1980; 6 : 2935.
  • 23
    Oreopoulos DG. Hepatitis and treatment of chronic renal failure by peritoneal dialysis. Lancet 1972; 2 : 1256.
  • 24
    Puttinger H, Vychytil A. Hepatitis B and C in peritoneal dialysis patients. Semin. Nephrol. 2002; 22 : 35160.
  • 25
    Hung KY, Shyu RS, Huang CH, Tsai TJ, Chen WY. Viral hepatitis in continuous ambulatory peritoneal dialysis patients in an endemic area for hepatitis B and C infection: The Taiwan experience. Blood Purif. 1997; 15 : 1959.
  • 26
    Centers for Disease Control. Recommendations for preventing transmission of infections among chronic hemodialysis patients. Morb. Mortal. Wkly. Rep. 2001; 50 : 143.
  • 27
    Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. Morb. Mortal. Wkly. Rep. 2004; 50 : 143.
  • 28
    United Kingdom Department of Health. Good Practice Guidelines for Renal Dialysis/Transplantation Units. Prevention and Control of Blood-Borne Virus Infection. London: Department of Health, 2002.
  • 29
    Community and Hospital Infection Control Association – Canada. Position Statement. Infection Prevention and Control Measures to Prevent Transmission of Hepatitis B among Hemodialysis Patients. Winnipeg: Canada. Community and Hospital Infection Control Association, 2007.
  • 30
    Centre for Healthcare Related Infection Surveillance and Prevention. Recommended Practices for the Prevention and Control of Infections in Dialysis Settings. Brisbane: Queensland Health, 2009.
  • 31
    Tele SA, Martins RM, Lopes CL, Dos Santos Carneiro MA, Souza KP, Yoshida CF. Immunogenicity of a recombinant hepatitis B vaccine (Euvax-B) in haemodialysis patients and staff. Eur. J. Epidemiol. 2001; 17 : 1459.
  • 32
    Centers for Disease Control. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR Recomm. Rep. 2001; 50 : 152.
  • 33
    Lanini S, Puro V, Lauria FN, Fusco FM, Nisii C, Ippolito G. Patient to patient transmission of hepatitis B virus: A systematic review of reports on outbreaks between 1992 and 2007. BMC Med. 2009; 7 : 15.
  • 34
    Centers for Disease Control. Outbreaks of hepatitis B virus infection among hemodialysis patients – California, Nebraska, and Texas, 1994. Morb. Mortal. Wkly. Rep. 1996; 45 : 2859.
  • 35
    Hoofnagle JH. Serologic markers of hepatitis B virus infection. Annu. Rev. Med. 1981; 32 : 111.
  • 36
    Ganem D, Prince AM. Hepatitis B virus infection – natural history and clinical consequences. N. Engl. J. Med. 2004; 350 : 111829.
  • 37
    Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373 : 58292.
  • 38
    Hui CK, Leung N, Yuen ST et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007; 46 : 395401.
  • 39
    Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion: Implication in anti-hepatitis B virus therapy. J. Gastroenterol. Hepatol. 2003; 18 : 24652.
  • 40
    Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long-term follow-up. Hepatology 2007; 45 : 118792.
  • 41
    Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: Mortality after 25 years. Gut 2008; 57 : 8490.
  • 42
    Di Stefano M, Volpe A, Stallone G et al. Occult HBV infection in hemodialysis setting is marked by presence of isolated antibodies to HBcAg and HCV. J. Nephrol. 2009; 22 : 3816.
  • 43
    Janzen L, Minuk GY, Fast M, Bernstein KN. Vaccine-induced hepatitis B surface antigen positivity in adult hemodialysis patients: Incidental and surveillance data. J. Am. Soc. Nephrol. 1996; 7 : 122834.
  • 44
    Krugman S, Giles JP, Hammond J. Viral hepatitis, type B (MS-2 strain) prevention with specific hepatitis B immune serum globulin. JAMA 1971; 218 : 166570.
  • 45
    Buynak EB, Roehm RR, Tytell AA, Bertland AU, Lampson GP, Hilleman MR. Vaccine against human hepatitis B. JAMA 1976; 235 : 28324.
  • 46
    Adkins JC, Wagstaff AJ. Recombinant hepatitis B vaccine: A review of its immunogenicity and protective efficacy against hepatitis B. BioDrugs 1998; 10 : 13758.
  • 47
    Zuckerman JN, Sabin C, Craig FM, Williams A, Zuckerman AJ. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: Randomised double blind dose-response study. BMJ 1997; 314 : 32933.
  • 48
    Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: Epidemiology and vaccination. Epidemiol. Rev. 2006; 28 : 11225.
  • 49
    Andre FE. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 1990; 8 (Suppl): S74S78.
  • 50
    McMahon BJ, Helminiak C, Wainwright RB, Bulkow L, Trimble BA, Wainwright K. Frequency of adverse reactions to hepatitis B vaccine in 43 618 persons. Am. J. Med. 1992; 92 : 2546.
  • 51
    Szmuness W, Stevens CE, Harley EJ et al. Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N. Engl. J. Med. 1980; 303 : 83341.
  • 52
    Crosnier J, Jungers P, Courouce AM et al. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: II, Haemodialysis patients. Lancet 1981; 1 : 797800.
  • 53
    Köhler H, Arnold W, Renschin G, Dormeyer HH. Meyer zum Buschenfelde KH. Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int. 1984; 25 : 1248.
  • 54
    Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N. Engl. J. Med. 1984; 311 : 496501.
  • 55
    Grob PJ, Binswanger U, Zaruba K et al. Immunogenicity of a hepatitis B subunit vaccine in hemodialysis and in renal transplant recipients. Antiviral Res. 1983; 3 : 4352.
  • 56
    Fujiyama S, Yoshida K, Sato T, Shimada H, Deguchi T. Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine in haemodialysis patients. Hepatogastroenterology 1990; 37 (Suppl 2): 14044.
  • 57
    Bruguera M, Rodicio JL, Alcazar JM, Oliver A, Del Rio G, Esteban-Mur R. Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients. Vaccine 1990; 8 (Suppl): S47S49.
  • 58
    Peces R, De La Torre M, Alcazar R, Urra JM. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am. J. Kidney Dis. 1997; 29 : 23945.
  • 59
    Guan R, Tay HH, Choong HL, Yap I, Woo KT. Hepatitis B vaccination in chronic renal failure patients undergoing haemodialysis: The immunogenicity of an increased dose of a recombinant DNA hepatitis B vaccine. Ann. Acad. Med. Singapore 1990; 19 : 7937.
  • 60
    Buti M, Viladomiu L, Jardi R et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am. J. Nephrol. 1992; 12 : 1447.
  • 61
    Agarwal SK, Irshad M, Dash SC. Comparison of two schedules of hepatitis B vaccination in patients with mild, moderate and severe renal failure. J. Assoc. Physicians India 1999; 47 : 1835.
  • 62
    DaRoza G, Loewen A, Djurdjev O et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: Earlier is better. Am. J. Kidney Dis. 2003; 42 : 118492.
  • 63
    Evans TG, Schiff M, Graves B et al. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination. Clin. Nephrol. 2000; 54 : 13842.
  • 64
    Jungers P, Devillier P, Salomon H, Cerisier JE, Courouce AM. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet 1994; 344 : 8567.
  • 65
    Miquilena-Colina ME, Lozano-Rodriguez T, Garcia-Pozo L et al. Recombinant interferon-alpha2b improves immune response to hepatitis B vaccination in haemodialysis patients: Results of a randomised clinical trial. Vaccine 2009; 27 : 565460.
  • 66
    Quiroga JA, Castillo I, Porres JC et al. Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology 1990; 12 : 6613.
  • 67
    Fabrizi F, Ganeshan SV, Dixit V, Martin P. Meta-analysis: The adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease. Aliment. Pharmacol. Ther. 2006; 24 : 78996.
  • 68
    Tong NK, Beran J, Kee SA et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 2005; 68 : 2298303.
  • 69
    Kong NC, Beran J, Kee SA et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int. 2008; 73 : 85662.
  • 70
    Chen W, Gluud C. Vaccines for preventing hepatitis B in health-care workers. Cochrane Database Syst. Rev. 2005; CD000100.
  • 71
    Fabrizi F, Dixit V, Magnini M, Elli A, Martin P. Meta-analysis: Intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment. Pharmacol. Ther. 2006; 24 : 497506.
  • 72
    Chau KF, Cheng YL, Tsang DN et al. Efficacy and side effects of intradermal hepatitis B vaccination in CAPD patients: A comparison with the intramuscular vaccination. Am. J. Kidney Dis. 2004; 43 : 91017.
  • 73
    Bock M, Barros E, Veronese FJ. Hepatitis B vaccination in haemodialysis patients: A randomized clinical trial. Nephrology (Carlton) 2009; 14 : 26772.
  • 74
    Barraclough KA, Wiggins KJ, Hawley CM et al. Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: A prospective open-label randomized controlled trial in nonresponders to primary vaccination. Am. J. Kidney Dis. 2009; 54 : 95103.
  • 75
    Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F. Intradermal versus intramuscular hepatitis b re-vaccination in non-responsive chronic dialysis patients: A prospective randomized study with cost-effectiveness evaluation. Nephrol. Dial. Transplant. 1997; 12 : 120411.
  • 76
    Weinstein T, Chagnac A, Boaz M et al. Improved immunogenicity of a novel third-generation recombinant hepatitis B vaccine in patients with end-stage renal disease. Nephron Clin. Pract. 2004; 97 : c67c72.
  • 77
    Rostaing L, Chatelut E, Payen JL et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: Clinical implications. J. Am. Soc. Nephrol. 1998; 9 : 23448.
  • 78
    Girndt M. Viral hepatitis in elderly haemodialysis patients: Current prevention and management strategies. Drugs Aging 2008; 25 : 82340.
  • 79
    Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol. Int. 2008; 2 : 16378.
  • 80
    Johnson MA, Verpooten GA, Daniel MJ et al. Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br. J. Clin. Pharmacol. 1998; 46 : 217.
  • 81
    Asari A, Iles-Smith H, Chen YC et al. Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end-stage renal failure. Br. J. Clin. Pharmacol. 2007; 64 : 73844.
  • 82
    Ben Ari Z, Broida E, Kittai Y, Chagnac A, Tur-Kaspa R. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation. Am. J. Gastroenterol. 2000; 95 : 357983.
  • 83
    Lapinski TW, Flisiak R, Jaroszewicz J, Michalewicz M, Kowalczuk O. Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation. World J. Gastroenterol. 2005; 11 : 4002.
  • 84
    Fontaine H, Thiers V, Chretien Y et al. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation 2000; 69 : 209094.
  • 85
    Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38 : 126773.
  • 86
    Kahn J, Lagakos S, Wulfsohn M et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial. JAMA 1999; 282 : 230512.
  • 87
    Izzedine H, Hulot JS, Launay-Vacher V et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies. Kidney Int. 2004; 66 : 11538.
  • 88
    Ha NB, Ha NB, Garcia RT et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009; 50 : 72734.
  • 89
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2005; 352 : 267381.
  • 90
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131 : 174351.
  • 91
    Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: A 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133 : 144551.
  • 92
    Fontaine H, Vallet-Pichard A, Chaix ML et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 2005; 80 : 108692.
  • 93
    Tillmann HL, Bock CT, Bleck JS et al. Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. Liver Transpl. 2003; 9 : 1916.
  • 94
    Gish RG, Lok AS, Chang TT et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133 : 143744.
  • 95
    Leung N, Peng CY, Hann HW et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 2009; 49 : 729.
  • 96
    Lok AS, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50 : 6612.
  • 97
    Jones R, Stebbing J, Nelson M et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: A cohort and case-control study. J. Acquir. Immune Defic. Syndr. 2004; 37 : 148995.
  • 98
    Patel SM, Zembower TR, Palella F, Kanwar YS, Ahya SN. Early onset of tenofovir-induced renal failure: Case report and review of the literature. ScientificWorldJournal 2007; 7 : 114048.
  • 99
    Kapitsinou PP, Ansari N. Acute renal failure in an AIDS patient on tenofovir: A case report. J. Med. Case Rep. 2008; 2 : 94.
  • 100
    Verhelst D, Monge M, Meynard JL et al. Fanconi syndrome and renal failure induced by tenofovir: A first case report. Am. J. Kidney Dis. 2002; 40 : 13313.
  • 101
    Izzedine H, Launay-Vacher V, Jullien V, Aymard G, Duvivier C, Deray G. Pharmacokinetics of tenofovir in haemodialysis. Nephrol. Dial. Transplant. 2003; 18 : 19313.
  • 102
    Kearney BP, Yale K, Shah J, Zhong L, Flaherty JF. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. Clin. Pharmacokinet. 2006; 45 : 111524.
  • 103
    Liaw YF, Leung N, Kao JH et al. Asian–Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol. Int. 2008; 2 : 26383.
  • 104
    Guh JY, Lai YH, Yang CY et al. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron 1995; 69 : 45965.
  • 105
    Harnett JD, Parfrey PS, Kennedy M, Zeldis JB, Steinman TI, Guttmann RD. The long-term outcome of hepatitis B infection in hemodialysis patients. Am. J. Kidney Dis. 1988; 11 : 21013.
  • 106
    Fabrizi F, Mangano S, Alongi G et al. Influence of hepatitis B virus virema upon serum aminotransferase activity in dialysis population. Int. J. Artif. Organs 2003; 26 : 104855.
  • 107
    Fabrizi F, Lunghi G, Alongi G et al. Biological dynamics of hepatitis B virus load in dialysis population. Am. J. Kidney Dis. 2003; 41 : 127885.
  • 108
    Tseng GY, Lin HJ, Fang CT et al. Hemodialysis reduces the viral load in uremic patients with chronic hepatitis B infection. Ren. Fail. 2008; 30 : 10005.
  • 109
    Barcena MR, Garcia GS. DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. World J. Gastroenterol. 2009; 15: 42330.
  • 110
    Fabrizi F, Messa P, Martin P. Hepatitis B virus infection and the dialysis patient. Semin. Dial. 2008; 21 : 44046.
  • 111
    Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002; 74 : 42737.